

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) dated 26 May 2022 in respect of the proposed adoption of the 2022 restricted A Share Incentive Scheme and the proposed issue and grant of new A Shares under the Incentive Scheme pursuant to Specific Mandate which involves connected transaction (the “**Announcement**”). Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Company will convene the AGM and the Class Meetings for Independent Shareholders to consider and, if thought fit, approve the resolutions in relation to, among others, the proposed Incentive Scheme, the Assessment Management Measures, the Specific Mandate for issue and allotment of the Restricted Shares under the Incentive Scheme and the grant of the Restricted Shares (including the grant to the Connected Participants under the First Grant) under the Incentive Scheme (the “**Incentive Scheme Resolutions**”). A circular (the “**Circular**”) containing, among other things, further details of the terms of the proposed Incentive Scheme, the proposed grant under the Incentive Scheme pursuant to the Specific Mandate, the recommendation from the Independent Financial Adviser and the letter from the Independent Board Committee on the issue and grant of Restricted Shares by the Company to the Connected Participants, will be despatched to the Shareholders on or before 9 June 2022.

As additional time is required for the discussion of the terms of the Incentive Scheme (including the provision of supplementary information in respect of and/or adjustment to the disclosed terms of the Incentive Scheme (if necessary)) and the preparation of the Circular, it is expected that the Incentive Scheme Resolutions will not be proposed at the AGM, and the despatch date of the Circular will be postponed to a date falling on or before 30 December 2022.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 8 June 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive directors.*

\* For identification purpose only